Literature DB >> 25943163

National tuberculosis prevalence surveys in Asia, 1990-2012: an overview of results and lessons learned.

Ikushi Onozaki1, Irwin Law1, Charalambos Sismanidis1, Matteo Zignol1, Philippe Glaziou1, Katherine Floyd1.   

Abstract

OBJECTIVE AND METHODS: In many countries, national tuberculosis (TB) prevalence surveys are the only way to reliably measure the burden of TB disease and monitor trends. They can also provide evidence about the current performance of TB care and control and how this could be improved. We developed an inventory of Asian surveys from 1953 to 2012 and then compiled and analysed a standard set of data for all national surveys implemented between 1990 (the baseline year for 2015 global TB targets) and 2012.
RESULTS: There were 21 surveys in 12 countries between 1990 and 2012; published results were available for 18. The participation rate was at least 80% and often much higher except for two surveys in Thailand. The prevalence of bacteriologically-positive TB disease among adults aged ≥15 years varied widely among countries (1.2 per 1000 population in China in 2010 to 15 per 1000 population in Cambodia in 2002), but age and sex distribution patterns were consistent with a progressive increase in rates of disease by age, and men accounting for 66-75% of prevalent cases. A high proportion of cases (40-79% across all surveys) did not report TB symptoms that met screening criteria (generally cough of 2-3 weeks or more, and blood in the sputum) and were only detected due to chest X-ray screening of all survey participants; this proportion increased over time in countries with repeat survey data. The ratio of prevalent cases to cases notified to national TB programmes was typically around two, but was as high as three in Lao PDR and Pakistan even after the internationally recommended TB control strategy had been implemented nationwide for several years. Four countries (China, Cambodia, the Republic of Korea and the Philippines demonstrated declines in smear or culture-positive pulmonary TB prevalence of approximately 50% over 10 years.
CONCLUSIONS: National TB prevalence surveys in Asia show that large reductions in the prevalence of TB disease can be achieved within a decade, that men bear much more of the burden than women and that the epidemic is ageing. Comparisons among countries show that more can be achieved in TB control in some countries with existing strategies and technologies. However, with many prevalent cases not reporting classic TB symptoms, all countries face the challenge of defining and implementing strategies that will result in earlier detection and treatment of cases.
© 2015 World Health Organization; licensed by Tropical Medicine & International Health Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Asia; Asie; epidemiology; epidemiología; estudio de prevalencia; prevalence survey; public health; salud pública; santé publique; surveillance de la prévalence; tuberculose; tuberculosis; épidémiologie

Year:  2015        PMID: 25943163     DOI: 10.1111/tmi.12534

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  70 in total

1.  Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.

Authors:  S Nourzad; H E Jenkins; M Milstein; C D Mitnick
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

Review 2.  Red Snappers and Red Herrings: Pelvic Tuberculosis Causing Elevated CA 125 and Mimicking Advanced Ovarian Cancer. A Case Report and Literature Review.

Authors:  Johnnie Alphonse Yates; Olivia Ann Collis; Thanasak Sueblinvong; Tarquin Kamakana Collis
Journal:  Hawaii J Med Public Health       Date:  2017-08

3.  Undiagnosed Active Pulmonary Tuberculosis among Pilgrims during the 2015 Hajj Mass Gathering: A Prospective Cross-sectional Study.

Authors:  Saber Yezli; Alimuddin Zumla; Yara Yassin; Ali M Al-Shangiti; Gamal Mohamed; Abdulhafiz M Turkistani; Badriah Alotaibi
Journal:  Am J Trop Med Hyg       Date:  2017-10-10       Impact factor: 2.345

Review 4.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

5.  TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings.

Authors:  I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

6.  Incidence and prevalence of bacteriologically confirmed pulmonary tuberculosis among adolescents and young adults: a systematic review.

Authors:  Kathryn J Snow; Lisa J Nelson; Charalambos Sismanidis; Susan M Sawyer; Stephen M Graham
Journal:  Epidemiol Infect       Date:  2018-04-15       Impact factor: 4.434

7.  The Epidemiological Importance of Subclinical Tuberculosis. A Critical Reappraisal.

Authors:  Emily A Kendall; Sourya Shrestha; David W Dowdy
Journal:  Am J Respir Crit Care Med       Date:  2021-01-15       Impact factor: 21.405

8.  Methods for estimating tuberculosis incidence and mortality by age and sex.

Authors:  Peter J Dodd; Charalambos Sismanidis; Philippe Glaziou
Journal:  Int J Epidemiol       Date:  2021-05-17       Impact factor: 7.196

9.  Trend analysis and longitudinal clustering of tuberculosis mortality in Asian and North African countries: Results from the global burden of disease 2017 study.

Authors:  Masoud Salehi; Nasim Vahabi; Hassan Pirhoseini; Farid Zayeri
Journal:  Med J Islam Repub Iran       Date:  2021-04-08

10.  Community drivers of tuberculosis diagnostic delay in Kampala, Uganda: a retrospective cohort study.

Authors:  Rachel Mercaldo; Christopher Whalen; Robert Kakaire; Damalie Nakkonde; Andreas Handel; Juliet N Sekandi
Journal:  BMC Infect Dis       Date:  2021-07-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.